DOCSLIB.ORG

Annual Report 2008 Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Annual Report 2008 Table of Contents Page 1 THE HISTORY OF THE GAIRDNER FOUNDATION Page 2 MISSION AND VISION Page 3 GOALS Page 4 MESSAGE FROM THE CHAIR Page 5 MESSAGE FROM THE PRESIDENT AND SCIENTIFIC DIRECTOR Page 6 2008 YEAR IN REVIEW Page 7-9 REPORT ON 2008 OBJECTIVES Page 10-11 THE YEAR AHEAD: OBJECTIVES FOR 2009 Page 12 2008 SPONSORS Page 13 GOVERNANCE Page 14 BOARD OF DIRECTORS 2008 Page 15 MEDICAL REVIEW PANEL 2008 Page 16 MEDICAL ADVISORY BOARD 2008 Page 17 GLOBAL HEALTH ADVISORY BOARD 2008 Page 18 GAIRDNER STAFF 2008 Page 19-30 2008 AUDITED FINANCIAL STATEMENTS THE GAIRDNER FOUNDATION Canada Gairdner 2008 Awardees. From L to R: Henry Friesen, M.D., Alan Bernstein, PhD. Harald zur Hausen, DSc., M.D., Samuel Weiss PhD., Nahum Sonenbrg, PhD., Victor Ambros, PhD., Gary Ruvkun, PhD. and John Dirks M.D. “The Gairdner Award is one of the world’s greatest biomedical research prizes. Where it leads, others follow, including the Nobel committees in Stockholm.” Paul Nurse, President of the Rockefeller University, Gairdner and Nobel Laureate The Gairdner Foundation was created in 1957 by Our track record of consistently high quality James Arthur Gairdner to recognize and reward the adjudication and selection by the independent achievements of medical researchers whose work adjudication committees, have resulted in global contributes significantly to improving the quality of recognition and esteem of the Gairdner Awards. human life. Since the first awards were made in 1959, the Gairdner Awards have become Canada’s In addition to encouraging and rewarding foremost international award. The Canada Gairdner individuals who have made contributions in International Awards are one of the three most the conquest of disease and the relief of human prestigious awards in medical science, along with suffering, the Foundation presents the Canada the Swedish Nobel Prize in Medicine and the Gairdner Awards in order to focus public, American Albert Lasker Medical Research Awards. professional and scientific attention on significant They hold up the pinnacle of achievement as a achievements in the field of health sciences. The mirror to Canadians, and in so doing, play a role in Awards also foster improved communication of helping Canada achieve its goals of excellence. ideas among scientists, students and the public. The Gairdner Foundation was incorporated in In 2009, the Gairdner Foundation will celebrate its December 1957 as a charitable corporation under the 50th anniversary, and will inaugurate the Canada laws of the Province of Ontario, Canada. Its funds Gairdner International Awards. originally derived from the personal gifts of the Founder and members of his family. This inspired and farsighted decision and the faithful stewardship by those who carried on the activities of the Foundation have ensured that the Awards continue to inspire the very best health research and have contributed to strengthening Canada’s scientific research capacity and international reputation. 1 THE GAIRDNER FOUNDATION - ANNUAL REPORT 2008 MISSION The mission of the Gairdner Foundation is to recognize and celebrate the work of the world’s best health researchers through the Canada Gairdner International Awards, the Gairdner Wightman Award and the Canada Gairdner Global Health Award. Inherent in our mission statement is the intent to bring to the attention of Canadian scientists and the public, the most important scientific developments globally in the field of health sciences. Our aim is not only to enhance Canada’s stature in the international scientific The Gairdner Foundation Vancouver Symposium © Don Erhardt From L to R: Charles Sabine, Harold Varmus M.D., Cynthia community, but to facilitate linkages Kenyon PhD. and Muin Khoury, M.D., PhD. between leading international scientists and Canadian research institutions and to inspire young Canadians to aspire to the highest levels of scientific excellence. VISION • To be Canada’s pre-eminent awards for the most significant international scientific achievements in health research • To be identified internationally with the highest standard of research excellence in the field of health sciences • To provide inspiration to Canadian researchers, including the next generation, to achieve world–class levels of scientific excellence • To promote a science culture in Canada by increasing public awareness of its importance to our modern society 2 THE GAIRDNER FOUNDATION - ANNUAL REPORT 2008 GOALS © Don Erhardt John H. Dirks M.D., President and Scientific Director, The Gairdner Foundation The goal of the Foundation is to maintain and expand the profile of the Canada Gairdner Awards program, guided by the Board, with a commitment to encouraging excellence and recognizing and rewarding those who achieve such excellence in the field of health sciences. A unique aspect of the Gairdner Foundation is our National Program, where award recipients contribute a week of their time visiting Universities across Canada. The National Program brings the world’s top scientists to Canada and helps raise the profile of science in our country. This program provides a unique opportunity for Canadian scientists and graduate students to interact with international leaders who represent the best of scientific excellence. “The Canada Gairdner Foundation Award is recognized as one of the world’s most prestigious awards in biomedical science.” Government of Canada (Science, Technology and Innovation Council). Canada’s Science, Technology and Innovation System: State of the Nation 2008. 3 THE GAIRDNER FOUNDATION - ANNUAL REPORT 2008 MESSAGE FROM THE CHAIR It has been my The Canada Gairdner Awards are Canada’s only privilege to serve as globally known and respected international Chair of the Gairdner prizes, and Gairdner is the only national Foundation Board of organization that consistently brings the world’s Directors for the past best biomedical researchers to Canada to share four years. During their ideas and work with scientists across the that time there have country. In so doing, it enlarges networks and been many changes enhances Canada’s international reputation to the Foundation: the while providing a realistic and unbiased shift from a private benchmark for Canada’s leading scientists. The to a public and truly Canada Gairdner Awards is a program that national Board; a $20 inspires Canadians to perform at world-class million allocation from levels of research and innovation. the Federal Government to raise the value of Biomedical research is international. Canada’s its prizes to $100,000; a significant endowment position in this critical global enterprise will from the Province of Alberta; the introduction be further strengthened during the 50th of a new Canada Gairdner Global Health Anniversary celebrations in 2009 through the Award; and significant growth in its outreach largest international celebration of science ever programs to universities and high schools held in Canada. It will take place throughout across Canada. the year and across the country in 18 different One thing has not changed – our commitment cities. to recognizing and celebrating excellence in Gairdner has accomplished much in its first science research. Over the past 50 years, the half century, but much more remains to be Canada Gairdner Awards have established done. Increasing the scope and the profile of themselves as one of the three most important the awards and the programs will enhance biomedical awards in the world. With a the culture of science in Canada. Because reputation for being a precursor to the Nobel Gairdner is a partnership organization, it Prize, they are widely respected by the will continue to leverage its national and biomedical research communities in Europe, international relationships to reach across Japan and North America. Over the past five provinces, universities, and health institutions years the Foundation has worked hard to use to encourage and contribute to the quest for its stature to raise awareness of the importance scientific discovery and innovation. of scientific research in Canada at the public, corporate and government levels. Henry Friesen, C.C., M.D., F.R.C.P.C., F.R.S.C. Chair, The Gairdner Foundation 4 THE GAIRDNER FOUNDATION - ANNUAL REPORT 2008 MESSAGE FROM THE PRESIDENT and SCIENTIFIC DIRECTOR The past year has been a transformative one I would also like to extend my sincere thanks and for the Gairdner Foundation, and we are appreciation to the staff of the Gairdner Foundation, particularly grateful to the Government of Canada who work diligently to make the programs for recognizing the value of the awards and successful every year. guaranteeing their existence for future generations. In its’ February 2008 budget, the Government Canada’s position in the critical enterprise of of Canada made a $20 million allocation to the biomedical research will be further strengthened Foundation to enable us to raise the value of the during the 50th Anniversary celebrations of 2009. prize to $100,000, a level befitting its’ international Symposia will take place across the country stature, and to make the prize more competitive throughout the year, bringing 50 Gairdner with other major prizes. Laureates, including 20 who have subsequently won the Nobel Prize, to participate in a series In 2009, the name of the awards will be changed to of international symposia featuring the best the Canada Gairdner International Awards. We will international and also inaugurate a new prize – the Canada Gairdner Canadian scientists. Global Health Award. We believe that this award, The 50th Anniversary the first major prize of its’ kind, will help bring will culminate with international recognition to the important role that a one-day event in Canada plays in the global health field and be a Ottawa and three catalyst for creating a world platform for Canada. days of events and programs in Toronto. Over the past year, we have focused on fostering Canada’s most partnerships among government, industry, prestigious scientific universities, research facilities and the general awards dinner will public, as we seek ongoing support for the take place in Toronto Foundation.
Recommended publications
  • Genetic and Epigenetic Mechanisms of the Regulation of Mouse Embryonic Stem Cells Self-Renewal by the Pluripotency Transcription Factor Nanog

    Genetic and Epigenetic Mechanisms of the Regulation of Mouse Embryonic Stem Cells Self-Renewal by the Pluripotency Transcription Factor Nanog

    Genetic and epigenetic mechanisms of the regulation of mouse embryonic stem cells self-renewal by the pluripotency transcription factor Nanog Victor HEURTIER Thèse de doctorat de Biologie Dirigée par Pablo NAVARRO GIL Laboratoire Epigénétique des cellules souches – Institut Pasteur Sorbonne Université Ecole doctorale Complexité du Vivant (ED 515) Présentée et soutenue publiquement le 18/09/2018 Devant un jury composé de : Président : Pr MOUCHEL-VIELH Emmanuèle, Professeur Rapporteur : Dr SAVATIER Pierre, Directeur de Recherche Rapporteur : Dr RADA-IGLESIAS Alvaro, Chef d’équipe Examinateur : Dr AZUARA Veronique, Maître de conférences Examinateur : Dr PINSKAYA Marina, Maître de conférences Directeur de thèse : Dr NAVARRO GIL Pablo, Chef d’équipe Abstract Mouse embryonic stem (ES) cells are derived from the pre-implantation blastocyst and are able to maintain their pluripotent state through virtually limitless cell divisions in vitro. The study of the mechanisms regulating the specific features of ES cells led to the discovery of the transcription factors (TFs) governing their unique transcriptome. Among those TFs, Nanog plays a central role in the gene regulatory network that supports ES cells self-renewal. However, the molecular mechanisms by which Nanog exerts its functions are not fully elucidated. We adapted an inducible CRISPR activation (CRISPRa) system in mouse ES cells and demonstrated its functionality to stimulate transcription at endogenous loci. We then accurately determined the list of Nanog responsive genes using gain (CRISPRa cell line) and loss of function experiments and total RNA sequencing. Moreover, the DNA binding profiles of distinct pluripotency TFs were assessed genome-wide by chromatin immunoprecipitation (ChIP) and sequencing upon Nanog depletion and revealed the importance of the latter in the regulation of the pluripotency network activity at thousands of loci.
  • Which Canadian Charities Had the Largest Assets in 2014?

    Which Canadian Charities Had the Largest Assets in 2014?

    www.canadiancharitylaw.ca Which Canadian charities had the largest assets in 2014? By Mark Blumberg (March 23, 2016) We recently reviewed the T3010 information for 2014. It covers about 84,370 of the 86,000 registered charities that have so far filed their return and that have been entered into the CRA’s database. Canadian registered charities are currently required to disclose on the T3010 their assets. The total assets of all the 84,370 registered charities were about $373,050,327,255.00. Below we have a table of Canadian charities and how much they spent as reported for the 2014 fiscal year. Thank you to Celeste Bonas, an intern at Blumbergs, for helping with this project. The Sean Blumberg Transparency Project is in memory of my youngest brother Sean Blumberg. Sean was a sweet, kind person, a great brother who helped me on a number of occasions with many tasks including the time consuming and arduous task of reviewing T3010 databases and making them into something useful. As part of the Sean Blumberg Transparency Project, Blumbergs has been releasing information on the Canadian charity sector to provide a better understanding of the size, scope, complexity and challenges of the sector. Please review my caveats at the end about the reliability and usage of T3010 information. 1 www.canadiancharitylaw.ca List of Canadian charities with the largest assets in 2014 Line 4200 Name of Canadian Registered Charity largest assets 1. ALBERTA HEALTH SERVICES $9,984,222,000.00 2. THE MASTERCARD FOUNDATION $9,579,790,532.00 3. THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO $7,681,040,000.00 4.
  • 2015 Annual Report

    2015 Annual Report

    1 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................. 2 HISTORY OF THE GAIRDNER FOUNDATION .................................................................................... 3 MISSION ...................................................................................................................................................... 3 NATIONAL AND STUDENT OUTREACH PROGRAMS ....................................................................... 4 MESSAGE FROM THE CHAIR ............................................................................................................... 5 MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR ......................................................... 6 2015 YEAR IN REVIEW ............................................................................................................................. 7 REPORT ON 2015 OBJECTIVES ............................................................................................................ 14 THE YEAR AHEAD: OBJECTIVES FOR 2016 ..................................................................................... 16 THE GAIRDNER FOUNDATION VALUES OUR 2015 SPONSORS ................................................... 18 GOVERNANCE ......................................................................................................................................... 20 MEDICAL REVIEW PANEL 2015 .........................................................................................................
  • 2015 Annual Summary Corporate Plan

    2015 Annual Summary Corporate Plan

    The Gairdner Foundation Corporate Plan 2015 1 TABLE OF CONTENTS PAGE Section I About the Gairdner Foundation 2 Objectives and Achievements to Date 5 Benefits 7 Section II Performance Results for 2014 Activities 7-8 Detailed 2014 Evaluations 9-10 Planned Activities and Anticipated Results 2015 11 Section III Financial Summary 12 Planned Receipts and Disbursements 2015 13-15 Section IV Risk Management 16 Section V Performance Monitoring 17-19 2 THE GAIRDNER FOUNDATION CORPORATE PLAN EXECUTIVE SUMMARY HISTORY The Gairdner Foundation was created by James A. Gairdner to recognize and reward the achievements of medical researchers whose work “contributes significantly to improving the quality of human life”. The Foundation is a Canadian organization that has never lost sight of its primary mission – the recognition of scientists it deemed to have made the most important breakthrough discoveries in biomedical science. It’s recipients are responsible for the discovery of the structure of DNA, the eradication of smallpox, CT scans, MRI machines, the human genome, the cure for ulcers, and the vaccine against HPV, to name a few. Since the first awards were granted in 1959, the Canada Gairdner Awards have become Canada's foremost international award- and one of the most prestigious awards in medical science. Our track record of consistent high quality adjudication and selection by the independent adjudication committees have resulted in global recognition and esteem. The Gairdner was incorporated in December 1957 as a charitable corporation under the laws of the Province of Ontario, Canada. During 2013, the Foundation was continued as a federal corporation under the Canada Not-For-Profit Corporations Act.
  • The Complex Life of the Complex Life Of

    The Complex Life of the Complex Life Of

    The Complex Life of mRNA EMBO|EMBL Symposium 5–8 October 2016 Heidelberg | Germany EMBL Advanced Training Centre KEYNOTE SPEAKERS Thomas Cech Patrick Cramer Jennifer Doudna University of Colorado Boulder, USA MPI for Biophysical Chemistry, Germany University of California, Berkley, USA ABSTRACT SUBMISSION DEADLINE CONFIRMED SPEAKERS 13 JULY 2016 Maria Barna Rachel Green Shona Murphy Stanford University, USA Johns Hopkins University Sir William Dunn School of Pathology, UK School of Medicine, USA REGISTRATION DEADLINE Simon Bullock Karla Neugebauer 24 AUGUST 2016 MRC Laboratory of Molecular Biology, UK Chuan He Yale University, USA The University of Chicago, USA Emmanuelle Charpentier Uwe Ohler MPI for Infection Biology, Germany Alan Hinnebusch Max Delbrueck Center, Berlin, Germany ORGANISERS NIH, USA Anne Ephrussi Jeffrey Chao Laura Ranum EMBL Heidelberg, Germany Friedrich Miescher Institute for Elisa Izaurralde University of Florida, USA Biomedical Research, Switzerland MPI for Developmental Biology, Germany Nahum Sonenberg Erin Schuman McGill University, Canada Elena Conti Jeff Kieft MPI for Brain Research, Germany MPI of Biochemistry, Germany University of Colorado, USA Joan Steitz Yukihide Tomari Yale University, USA Victoria D'Souza Iain MacRae The University of Tokyo, Japan Harvard University, USA The Scripps Research Institute, USA David Tollervey Jonathan Weissman Wellcome Trust Centre for Cell Biology, UK Caroline Dean James Manley University of California, John Innes Centre, UK Columbia University, USA San Francisco, USA Additional speakers will be Gideon Dreyfuss Christine Mayr Marat Yusupov selected from abstracts. Perelman School of Medicine at the Memorial Sloan Kettering Cancer Institute of Genetics and Molecular University of Pennsylvania, USA Center, USA and Cellular Biology (IGBMC), France CONTACT www.embo-embl-symposia.org [email protected].
  • Bulletin the Canadian Society for Molecular Biosciences La Société Canadienne Pour Les Biosciences Moléculaires

    Bulletin the Canadian Society for Molecular Biosciences La Société Canadienne Pour Les Biosciences Moléculaires

    Bulletin The Canadian Society for Molecular Biosciences La Société Canadienne pour les Biosciences Moléculaires 2013 www.csmb-scbm.ca Bulletin The Canadian Society for Molecular Biosciences La Société Canadienne pour les Biosciences Moléculaires 2013 www.csmb-scbm.ca Cover images were provided by Dr. Benoit Chabot (see article standing on p32). 2 CSMB | SCBM Bulletin 2013 CSMB Board for 2013 ...............................................................................................................................................................5 President’s Report 2013 .........................................................................................................................................................7 Incoming Member of the Executive Board Martin Bisaillon, Councillor ...............................................................................................................................................9 Minutes of the 56th Annual General Meeting 2013 ...................................................................................................10 Financial Statement 2013 ....................................................................................................................................................12 56th Annual Meeting, Niagara-on-the Lake Meeting Schedule ..............................................................................................................................................................17 Scenes from the Meeting .................................................................................................................................................25
  • Dr. Adolfo J. De BOLD

    Dr. Adolfo J. De BOLD

    Dr. Adolfo J. de BOLD September 2015 Page 1 of 40 HOME ADDRESS: OFFICE ADDRESS: 5503 South Island Park Drive Department of Pathology and Laboratory Manotick, Ontario K4M 1J2 Medicine Phone: (613) 692-6194 University of Ottawa, Faculty of Medicine 4155-451 Smyth Road Ottawa, Ontario K1H 8M5 Phone: (613) 562-5422 [email protected] EDUCATION 1961 - 1967 National University of Córdoba, Argentina 1968 Professional Degree: Clinical Biochemist 1968 - 1973 School of Graduate Studies, Queens University, Kingston, Ontario, Canada 1971 M.Sc. (Experimental Pathology) "Studies on the Relationship between the Catecholamine Distribution in the Atrium and the Specific Granules Present in Atrial Muscle Cells" 1973 Ph.D. (Experimental Pathology) "The Relationship Between Morphology and Function in the Atrial Cardiocyte. A study With Emphasis on the Secretory Characteristics of the Mammalian Atrium" PROFESSIONAL APPOINTMENTS 1974 Laboratory Scientist, Pathology Laboratory, Hotel Dieu Hospital, Kingston, Ontario, Canada. 1974 Assistant Professor of Pathology, Department of Pathology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada (Tenured, 1981). 1982 Associate Professor of Pathology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada. 1985 Professor of Pathology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada. 1986-1993 Director of Research, University of Ottawa Heart Institute Research Centre, Ottawa Civic Hospital. 1989-1995 Distinguished Research Professor, Heart and Stroke Foundation of Ontario. 1986-1995 Adjunct Professor of Pathology, Queen's University, Kingston, Ontario, Canada. 1986-2013 Professor of Pathology and Laboratory Medicine Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada 1986-2013 Cross-appointment, Department of Cellular and Molecular Medicine, Faculty of Dr. Adolfo J.
  • NCI Budget Fact Book for Fiscal Year 1996

    NCI Budget Fact Book for Fiscal Year 1996

    NCI FACT BOOK National Cancer Institute 1996 U.S. DEPARTMENT NATIONAL INSTITUTES OF HEALTH AND OF HEALTH HUMAN SERVICES The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892. TABLE OF CONTENTS Page Organization Director's Biography ........................................ 1 Former Directors of the NCI .................................. 2 National Cancer Advisory Board .............................. 3 Division Boards of Scientific Counselors ........................ 4 President's Cancer Panel .................................... 5 Executive Committee Members ............................... 5 Organization Charts: National Cancer Institute ................................... 6 Office of the Director ...................................... 7 Division of Basic Sciences .................................. 8 Division of Clinical Sciences ................................ 9 Division of Cancer Epidemiology and Genetics ................. 10 Division of Cancer Prevention and Control .................... 11 Division of Cancer Treatment, Diagnosis and Centers ............ 12 Division of
  • Ed 376 019 Title Institution Pub Date Note Available From

    Ed 376 019 Title Institution Pub Date Note Available From

    DOCUMENT RESUME ED 376 019 SE 053 531 TITLE Grants for Science Education, 1992-1993. INSTITUTION Howard Hughes Medical Inst., Chevy Chase, MD. Office of Grants and Special Programs. PUB DATE 93 NOTE 141p. AVAILABLE FROMHoward Hughes Medical Institute, Office of Grants and Special Programs, 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789. PUB TYPE Guides Non-Classroom Use (055) EDRS PRICE MF01/PC06 Plus Postage. DESCRIPTORS *Biomedicine; *Grants; Higher Education; *Research; *Science Education; Secondary Education ABSTRACT To help strengthen education in medicine, biology, and related sciences, the Howard Hughes Medical Institute (HHMI) launched a grants program in these areas in 1987. The grants support graduate, undergraduate, precollege and public science education, and fundamental biomedical research abroad. This document provides summaries of all projects receiving grants in 1992 and is also, in effect, a 1992 annual report for each Programmatic Area supported by HHMI. (ZWH) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made from the original document. *********************************************************************** 9- -.I I, .10 It vr .. * ie Ar -4",_ -7 \---(_,- 1 a Si It I 1 a a I tIt "PERMISSION TO REPRODUCETHIS U S DEPARTMENT OF EDUCATION GRANTED BY Orrice of Educahona, Research and irnomvernent MATERIAL HAS BEEN EDUCATIONAL RESOURCES INFORMATION CENTER (EPICI U ER-P,C This document has been reproduced as owed Iron the person or Organitation originating it C.1 Minor changes name been made to improve reproduction quality TO THE EDUCATIONALRESOURCES Ponis of vev, o ot),n(Ons staled .nlh'S doc 0 meal do not necessarily represent othc,a1 INFORMATION CENTER (ERIC) OE RI pc on or policy I I I a I -SET COPYAWAt'tMI 2 Copyright ©1993 by the Howard Hughes Medical Institute Office of Grants and Special Programs.
  • Profile of Nahum Sonenberg PROFILE Ann Griswold, Science Writer

    Profile of Nahum Sonenberg PROFILE Ann Griswold, Science Writer

    PROFILE Profile of Nahum Sonenberg PROFILE Ann Griswold, Science Writer Five years after the final shots of World War II rang out, a child and his father stood on the coast of the Mediterranean Sea. From their vantage point in a cemetery in the town of Jaffa, Israel, the boy gazed across the sea and envisioned stepping onto the sands of a distant shore. He pointed to the horizon and asked his father what lay beyond. “I remember my father said, ‘There is America, the country where everything is possible,’” says Nahum Sonenberg, the Gilman Cheney Professor of Biochem- istry at McGill University in Montreal. Sonenberg, elected as a foreign associate to the National Academy of Sciences in 2015, has spent nearly five decades looking beyond the horizon to map un- explored territory in molecular biology. His research has uncovered the cellular control knobs of protein synthesis and revealed how this process drifts off-course in cancer, obesity, diabetes, and neurological diseases. His achievements have garnered numerous hon- ors. Sonenberg is a fellow of the Royal Society of London and Canada, Foreign Member of the Amer- ican Academy of Arts and Sciences and the American Association for the Advancement of Science, Asso- ciate Member of European Molecular Biology Orga- nization, and an Officer of the Order of Canada. He has received numerous prizes in the biological sciences, including the Lewis S. Rosenstiel Award for Distin- guished Work in Basic Medical Science, the Wolf Prize, and the Gairdner Foundation International Award. Nahum Sonenberg. Image courtesy of Howard Hughes Medical Institute. Life in Transition Sonenberg’s childhood unfolded in the aftermath of By the time Sonenberg turned 10, he and his family had World War II.
  • The Magic Is the Protein.’’ Don’T Wait a Lifetime for a Decision

    The Magic Is the Protein.’’ Don’T Wait a Lifetime for a Decision

    Vol. 19 / No. 4 / April 2020 THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY ‘‘ The magic isn’t the squid… The magic is the protein.’’ Don’t wait a lifetime for a decision. C. elegans daf-2 mutants can live up to 40 days. JBC takes only 17 days on average to reach a fi rst decision about your paper. Learn more about fast, rigorous review at jbc.org. www.jbc.org NEWS FEATURES PERSPECTIVES 2 22 37 EDITOR’S NOTE ‘THE MAGIC ISN’T THE SQUID ... USE THE MIC! Caution: Tchotchkes at work The magic is the protein.’ 38 3 28 WHAT CAN YOUR OMBUDS OFFICE MEMBER UPDATE ‘START SIMPLE. IT ALWAYS GETS DO FOR YOU? MORE COMPLICATED.’ 6 A conversation with Paul Dawson IN MEMORIAM 10 ANNUAL MEETING RETROSPECTIVE Marilyn Farquhar (1928 – 2019) 32 MOLECULAR & CELLULAR PROTEOMICS SESSION 13 LIPID NEWS 32 A deeper insight into phospholipid MCP TO HOST PROTEOMICS SESSION biosynthesis in Gram-positive bacteria 33 GINGRAS STUDIES PROTEOMICS’ IMPLICATIONS FOR RESEARCH 14 34 JOURNAL NEWS SELBACH SEEKS THE SCIENCE BEHIND THE MAGIC 14 Scrutinizing pigs’ biggest threat 35 15 Progesterone from an unexpected source GARCIA USES MASS SPECTRONOMY TO UNRAVEL THE HUMAN EPIGENOME may affect miscarriage risk 16 Finding neoantigens faster — advances in the study of the immunopeptidome Don’t wait a lifetime for a decision. 18 From the journals C. elegans daf-2 mutants can live up to 40 days. JBC takes only 17 days on average to reach a fi rst decision about your paper. Learn more about fast, rigorous review at jbc.org.
  • “Global Health Research”?

    “Global Health Research”?

    32 International Health: Feature Article Volume 3 No. 1, 2006 INTERNATIONAL HEALTH: FEATURE ARTICLE What is Canada Doing About “Global Health Research”? Vic Neufeld, MD, FRCPC ABSTRACT The worldwide investment in health research is currently about US$100 billion. Of this amount, less than 10% is targeted on the problems of societies that bear 90% of the global burden of illness. This article addresses this unac- ceptable situation in three ways: • by describing the global problem in more detail, including what is currently being done about it; • by summarizing Canada’s contribution to resolving the problem, both through federal government agencies, and through a new non-government organization: the Canadian Coalition for Global Health Research (CCGHR); • by suggesting what Canadian university students might consider doing about it. This includes getting informed, getting involved, and considering “global health” as one component of their future careers. The article concludes with the conviction that this is a remarkable moment for Canadians to play a more active role in global health—and indeed in global citizenship more broadly. WHAT IS CANADA DOING ABOUT “GLOBAL about the fact that research efforts to address this burden HEALTH RESEARCH”? appeared to be too small and ineffective. A major 2-year study was undertaken by the Independent International Commission n 2002, the worldwide investment in health research was on Health Research for Development (CHRD). The about US$100 billion. It is a startling fact that of this Commission released what has become a landmark report in Iamount, less than 10% was directed to research on problems 1990.1 Among its findings, the CHRD reported that about 93% of societies that bear 90% of the global burden of illness.